• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

    6/27/23 8:19:37 AM ET
    $ACET
    $AEL
    $ASTC
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Life Insurance
    Finance
    Get the next $ACET alert in real time by email

    Gainers

    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares surged 49.8% to $0.3401 in pre-market trading after dropping around 19% on Monday. Surgalign Holdings recently entered into an asset purchase agreement to sell its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings for $5 million.
    • BIOLASE, Inc. (NASDAQ:BIOL) shares gained 23.4% to $0.0969 in pre-market trading. Biolase was recently notified by Nasdaq that the company did not meet the minimum closing bid price requirement of $1.00 for continued listing.
    • InnSuites Hospitality Trust (NYSE:IHT) shares rose 17.2% to $3.06 in pre-market trading after gaining 13% on Monday.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares rose 17% to $0.5842 in pre-market trading. Avalo Therapeutics shares dipped around 89% on Monday after the company released topline results from the Phase 2 PEAK trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with poorly controlled non-eosinophilic asthma (NEA).
    • View, Inc. (NASDAQ:VIEW) shares climbed 15% to $0.1381 in pre-market trading after declining around 10% on Monday. View recently filed a new patent application titled "Environmental Adjustment Using Artificial Intelligence."
    • Design Therapeutics, Inc. (NASDAQ:DSGN) rose 14.5% to $6.59 in pre-market trading.
    • Astrotech Corporation (NASDAQ:ASTC) gained 14.3% to $13.03 in pre-market trading. Astrotech 13D filing showed BML Investment Partners, L.P. increased stake in the company to 13%.
    • OneConnect Financial Technology Co., Ltd. (NASDAQ:OCFT) shares gained 11.5% to $3.08 in pre-market trading after dropping 33% on Monday. The company recently reported first-quarter sales of $135.33 million, missing the consensus estimate of $143.91 million.
    • IronNet, Inc. (NYSE:IRNT) gained 11.2% to $0.2003 in pre-market trading after dropping 13% on Monday.
    • American Equity Investment Life Holding Company (NYSE:AEL) rose 8.7% to $49.00 in pre-market trading following a report suggesting Brookfield is nearing a deal to acquire the company.

    Losers

    • Lordstown Motors Corp. (NASDAQ:RIDE) fell 56.2% to $1.21 in pre-market trading after the company opted to file for Chapter 11 bankruptcy protection.
    • Digital Media Solutions, Inc. (NYSE:DMS) fell 18.2% to $0.3330 in pre-market after jumping around 22% on Monday.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) fell 18.1% to $13.40 in pre-market trading after surging 94% on Monday. The company announced on Friday that it will acquire Superlatus.
    • Spark Networks SE (NASDAQ:LOV) fell 16.7% to $0.35 in pre-market trading after jumping 50% on Monday. Spark Networks recently received notice from Nasdaq advising it has determined to deny the company's request for continued listing.
    • Adicet Bio, Inc. (NASDAQ:ACET) fell 14.2% to $4.00 in pre-market trading after the company reported data from ongoing ADI-001 Phase 1 trial in patients with relapsed or refractory aggressive B-Cell Non-Hodgkin's Lymphoma. JMP Securities downgraded Adicet Bio from Market Outperform to Market Perform.
    • iMedia Brands, Inc. (NASDAQ:IMBI) shares dropped 13.3% to $0.1648 in pre-market trading after jumping 35% on Monday. iMedia Brands recently announced receipt of second Nasdaq non-compliance notice.
    • Evelo Biosciences, Inc. (NASDAQ:EVLO) shares fell 12.5% to $0.1749 in pre-market trading after gaining around 18% on Monday. Evelo Biosciences recently won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome.
    • VIQ Solutions Inc. (NASDAQ:VQS) fell 11.8% to $0.3170 in pre-market trading. VIQ Solutions recently partnered Justice AV Solutions to bring AI-generated draft transcripts of courtroom proceedings.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) fell 10.2% to $0.30 in pre-market trading after gaining around 10% on Monday.
    • Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares dropped 9.2% to $0.31 in pre-market trading after gaining 8% on Monday.

     

    Now Read This: Investor Optimism Declines After US Stocks Record Weekly Loss

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET
    $AEL
    $ASTC
    $AVTX

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Design Therapeutics Inc.
    $DSGN
    1/7/2026$18.00Outperform
    Oppenheimer
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$14.00Market Perform → Outperform
    Leerink Partners
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$15.00Buy
    Craig Hallum
    Design Therapeutics Inc.
    $DSGN
    11/20/2025$13.00Sector Perform → Outperform
    RBC Capital Mkts
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    OneConnect Financial Technology Co. Ltd.
    $OCFT
    9/8/2025Buy → Neutral
    Citigroup
    More analyst ratings

    $ACET
    $AEL
    $ASTC
    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

    WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare ConferenceFireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global Healthcare ConferenceFireside ChatMarch 10, 2026, at 4:20 pm ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for

    2/24/26 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IHT ANNOUNCES BREAKTHROUGH IN UNIGEN DIVERSIFICATION PROJECT INVESTMENT

    Phoenix, AZ, Feb. 23, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) On December 16, 2019, InnSuites Hospitality Trust made a $1 Million diversification investment in UniGen Power, Inc. A major breakthrough has occurred in the UniGen Power Inc. quest to successfully raise the next round of financing focused on completing engineering previously reported at 61% complete. This new financing could soon allow UniGen to complete the first two 1000NT new innovation prototypes. On February 20, 2026, the recently reconstituted UniGen Board elected an all-new management team electing James Wirth (IHT President, CEO, and Chairman) to fill vacant UniGen positions as President, CEO, a

    2/23/26 6:25:00 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

    WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the "Options") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on February 13, 2026 and have an exercise price of $14.

    2/18/26 4:05:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AEL
    $ASTC
    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc bought $5,000,000 worth of shares (5,000,000 units at $1.00) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    10/10/25 8:06:01 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wirth James F bought $116,550 worth of INNSUITES HOSPITALITY REIT (300 units at $388.50), increasing direct ownership by 0.00% to 6,252,496 units (SEC Form 4)

    4 - INNSUITES HOSPITALITY TRUST (0000082473) (Issuer)

    5/31/24 4:25:12 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    $ACET
    $AEL
    $ASTC
    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Design Therapeutics with a new price target

    Oppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00

    1/7/26 9:09:56 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AEL
    $ASTC
    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Aftab Blake covered exercise/tax liability with 535 shares, decreasing direct ownership by 15% to 2,981 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:46:53 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Healey Don covered exercise/tax liability with 535 shares, decreasing direct ownership by 13% to 3,452 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:46:12 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Schor Chen covered exercise/tax liability with 1,755 shares, decreasing direct ownership by 20% to 6,820 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:45:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AEL
    $ASTC
    $AVTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/24/26 4:48:09 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/17/26 6:13:19 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.

    SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

    2/17/26 4:27:23 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AEL
    $ASTC
    $AVTX
    Leadership Updates

    Live Leadership Updates

    View All

    Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

    AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent Developments Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and As

    2/13/26 8:15:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

    AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") today announced that its subsidiary, 1st Detect Corporation ("1st Detect"), has appointed industry veteran, David Spada, as Director of Global Sales. This strategic hire strengthens 1st Detect's commercial leadership as the company scales deployment of its TRACER 1000™ mass spectrometry-based explosives and narcotics trace detector across international security markets. Mr. Spada brings over a decade of specialized trace detection experience to the 1st Detect team. Throughout his career at Implant Sciences, Morpho Detection, and Rapiscan Systems, Mr. Spada has held position

    1/21/26 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Corporation Appoints Scott Bartley as Interim Chief Financial Officer

    AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or ("Astrotech"), today announced that it has appointed Scott Bartley as Interim Chief Financial Officer ("CFO") of the Company, effective as of October 20, 2025. "We are pleased to announce Scott Bartley as Chief Financial Officer," stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation. "He brings over two decades of expertise as a Controller and CFO, across multiple industries, providing important qualification and vantage points for our business across multiple end markets."​Mr. Bartley, age 56, has served as a financial consultant since 2011, inclu

    10/31/25 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACET
    $AEL
    $ASTC
    $AVTX
    Financials

    Live finance-specific insights

    View All

    IHT DECLARES 56TH CONSECUTIVE ANNUAL DIVIDEND AS HOTEL REVENUES SURGE

    Phoenix, AZ, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) On January 12, 2026, the Board of Trustees of InnSuites Hospitality Trust (NYSE Am: IHT), announced a semi-annual dividend of $0.01 per share payable on February 9, 2026, to shareholders of record as of January 27, 2026, extending an uninterrupted continuous 56-year history of annual dividends. InnSuites Hotel operations continue to remain strong, with a combined revenue total in December for the two hotels of $536,399. We are also pleased to report record revenues for the two hotels combined for the month of December 2025, and project record hotel total Revenues for our IHT hotels for the 2026 Fiscal Ye

    1/21/26 5:27:00 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    IHT FISCAL FIRST THREE QUARTER HOTEL REVENUES EXCEED $5.8 MILLION; IBC DIVERSIFICATION GAINS MOMENTUM

    Phoenix, AZ, Dec. 15, 2025 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) reported Hotel Revenue results surpassing $5.8 million once again in the First Three Fiscal Quarters of 2026, (February 1, 2025, to October 31, 2025), with Total Revenue of approximately $5,809,673. Consolidated Net Income before the non-cash expense of depreciation and the non-cash Best Western Rewards Guest Vouchers expense, was approximately break-even at (-48,000), for the 2026 First Fiscal Three Quarters ended October 31, 2025 (February 1, 2025, through October 31, 2025). IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025, and are contributing to a comparable 2026 Fisca

    12/15/25 5:29:00 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

    -Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician's Global Assessment (PGA) highlighting ADI-001's potential for durable effect on a broad range of lupus symptoms- -As of the August 31, 2025 data cut-off date, all five LN patients experienced improved renal function, including three complete renal responses and Definition Of Remission In Systemic lupus erythematosus (DORIS) rem

    10/7/25 6:45:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AEL
    $ASTC
    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 5:46:11 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 4:05:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care